Federal regulators approved Moderna’s vaccine against Respiratory Syncytial Virus (RSV) for some adults as young as 18, the company said on June 12.
The Food and Drug Administration (FDA) expanded approval of the shot to people aged 18 to 59 who face an increased risk from RSV, a virus that typically causes cold-like symptoms, Moderna said in a statement.
The FDA, which in 2024 approved the vaccine for adults aged 60 and up, did not respond to a request for comment.
“RSV poses a serious health risk to adults with certain chronic conditions, and today’s approval marks an important step forward in our ability to protect additional populations from severe illness from RSV,” Stéphane Bancel, Moderna’s CEO, said in a statement….